Medical Information Only: This medication is not sold on this site. The information provided is for reference purposes only. Please consult your local physician or pharmacist for treatment.

liraglutide/insulin degludec (IDegLira): Dosing and Uses

 

Classes: Antidiabetics, Insulins; Antidiabetics, Long-Acting Insulins; Antidiabetics, Glucagon-like Peptide-1 Agonists

Medically reviewed by Min Clinic Staff | Updated: January 2026

Dosing and uses of IDegLira (liraglutide/insulin degludec)

 

Type 2 Diabetes Mellitus

Pending FDA approval for treatment of adults with type 2 diabetes mellitus

 

Pediatric dosage forms and strengths

Safety and efficacy not established

 

Pharmacology of IDegLira (liraglutide/insulin degludec)

Mechanism of action

Insulin degludec: Long-acting basal insulin; lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production; insulin inhibits lipolysis and proteolysis and enhances protein synthesis; targets include skeletal muscle, liver, and adipose tissue

Liraglutide: Incretin mimetic; analogue of human glucagonlike peptide-1 (GLP-1); acts as GLP-1 receptor agonist to increase insulin secretion in the presence of elevated blood glucose; delays gastric emptying to decrease postprandial glucose; also decreases glucagon secretion